Consistent with this finding are the clinical studies that showed that high levels of EZH2 are only associated with a proportion of synovial sarcoma patients [29,30], suggesting caution on EZH2 inhibitor implication in the clinical setting. The gene discussed is EZH2; the disease is synovial sarcoma.